Company Overview

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. In 2023, Novartis completed its transformation into a "pure-play" innovative medicines business. The company has a clear focus on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. These areas feature multiple significant in-market and pipeline assets, addressing high disease burden and demonstrating substantial growth potential.

Market Position and Financial Performance

Novartis AG achieved a market value of $238.27 billion as of October 16, 2024. The company has demonstrated exceptional financial performance, with sales growing 12% (constant currency) and core operating income growing 22% (constant currency) in 2024. This represents one of the strongest financial performances in its history, marking its first full year as a pure-play innovative medicines business following the Sandoz spin-off completion in October 2023.

Key Financial Highlights (2024):

- Sales Growth: 12% constant currency

- Core Operating Income Growth: 22% constant currency

- Free Cash Flow: USD 16.3 billion (+24% USD)

- Proposed Dividend: CHF 3.50 per share for 2024 (up 6.1% from prior year)

Core Therapeutic Areas and Key Products

Novartis operates across four primary therapeutic areas, each contributing significantly to the company's growth trajectory.

Cardiovascular-Renal-Metabolic

Entresto remains a standout performer in the cardiovascular space, with sales growth driven by its continued strong performance (+34% cc) in 2024. This heart failure treatment has consistently exceeded expectations, with peak sales projections reaching USD 7 billion.

Immunology

Cosentyx continues its strong momentum with 24% growth (cc) in 2024. Xolair (for allergic asthma and nasal polyps) and other immunology assets also contribute to this therapeutic area's success.

Kesimpta has shown remarkable growth trajectories, achieving 49% growth (cc) in 2024, primarily driven by increased demand in the multiple sclerosis market.

Oncology

The oncology portfolio includes several high-growth products:

- Kisqali: The breast cancer treatment achieved 52% growth (cc) in 2024.

- Pluvicto: Used to treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

- Scemblix: For chronic myeloid leukemia treatment.

Other Key Products

- Leqvio: The cholesterol-lowering drug showed exceptional growth of 83% (cc) in 2024.

- Zolgensma: For the treatment of the genetic root cause of spinal muscular atrophy.

Technology Platforms and Innovation

In addition to two established technology platforms (chemistry and biotherapeutics), three emerging platforms (gene & cell therapy, radioligand therapy, and xRNA) are being prioritized for continued investment into new R&D capabilities and manufacturing scale. The company maintains a robust pipeline with 15 submission-enabling readouts expected over the coming years and more than 30 assets with the potential to drive differentiated growth over the long term.

Capital Allocation and Shareholder Returns

Novartis maintains a disciplined approach to capital allocation, balancing investments to create sustainable value for shareholders. The company has an ongoing share buyback program, with CHF 3.5 billion remaining under the authority granted at the 2023 Annual General Meeting. The Novartis Board of Directors proposes a dividend payment of CHF 3.50 per share for 2024, marking the 28th consecutive dividend increase since Novartis's creation in December 1996.

Strategic Focus and Growth Outlook

With the current business momentum, Novartis expects to continue strong sales growth with margin expansion in 2025 and remains on track to deliver on its mid-term guidance. Key geographic markets include the US, China, Germany, and Japan. Recent strategic moves involve partnerships and acquisitions to strengthen the pipeline, including licensing agreements and strategic acquisitions to enhance capabilities in areas like gene therapy and neuroscience.

Innovation Milestones

Novartis also achieved important innovation milestones, including new approvals and readouts for many assets that will fuel its future growth. The company continues to advance its pipeline across multiple therapeutic areas, with particular strength in radioligand therapy and targeted treatments.

Novartis stands as a leading pharmaceutical company with a clear strategic focus on innovative medicines, strong financial performance, and a robust pipeline positioned to drive sustainable growth across its core therapeutic areas.